I am a board-certified medical oncologist and work as part of a multidisciplinary team to care for patients with breast cancer. In my clinical research I focus on developing more-effective and less-toxic treatment strategies for women with this disease. My particular interest is in evaluating combination therapies that include anti-HER2 drugs with chemotherapy in the treatment of patients with early-stage and metastatic HER2-positive breast cancer.
My research has changed standard practice. For example, the widespread use and National Comprehensive Cancer Network (NCCN) endorsement of a dose-dense, anthracycline/taxane-containing chemotherapy regimen followed by trastuzumab in patients with early stage HER2-positive breast cancer was a direct consequence of an investigator-initiated trial that I led at Memorial Sloan Kettering. Additionally, I led another investigator-initiated study that evaluated dual anti-HER therapy with trastuzumab and pertuzumab and chemotherapy for patients with HER2-positive metastatic breast cancer. This led to the NCCN endorsement of this regimen as a standard option in treating patients with metastatic HER2-positive breast cancer. A third investigator-initiated study on dual anti-HER2 therapy with trastuzumab and lapatinib with chemotherapy also had an impact on research worldwide. I am currently leading other research trials, both locally and internationally. From these studies and others, I have also focused on the unique cardiac toxicities of anthracyclines and anti-HER2 agents. To allow for improved patient selection and monitoring, I am studying cardiac biomarkers, with a future goal of facilitating early interventions to minimize acute and late cardiac effects of cancer treatment.
New therapies have greatly improved the prognosis for many breast cancer patients, but some treatments produce side effects that appear years after the completion of treatment. My colleagues and I are working to develop markers or predictors to identify the patients who may be at risk of developing early, and possibly late, complications such as heart damage so that we can design early interventions to prevent these side effects — for example, by adding a cardiac drug to treatment to minimize heart problems in the future.
- Clinical Expertise: Breast Cancer
- Languages Spoken: English
- Education: MD, Medical University of South Carolina
- Residencies: Allegheny General Hospital/Medical College of Pennsylvania
- Fellowships: NewYork-Presbyterian Hospital
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Chau T. Dang
- A Phase II Study of Gemcitabine plus HER2-Targeting Therapies in Women with Persistent HER2-Positive Advanced Breast Cancer
- A Phase II Study of Pertuzumab and Trastuzumab with Standard Chemotherapy Given Before Surgery in Patients with Locally Advanced, Inflammatory, and Early-Stage HER2-Positive Breast Cancers
- A Phase II Study of Trastuzumab Emtansine versus Trastuzumab/Paclitaxel in Women with Stage I HER2-Positive Breast Cancer
Clinical Trials Co-Investigated by Chau T. Dang
- A Phase II Study to See if Carvedilol Can Help Prevent Heart Function Problems in Women Receiving Anthracyclines or Anti-HER2 Therapies for Breast Cancer
- A Phase III Study of Hormone Therapy with and without Chemotherapy in Patients with HER2-Negative Breast Cancer and 1-3 Positive Lymph Nodes and a Recurrence Score of 25 or Less
- Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults